The global buccal drug delivery system market size is expected to reach USD 6.31 billion by 2030, according to a new study by Polaris Market Research. The report “Buccal Drug Delivery System Market Share, Size, Trends, Industry Analysis Report, By Type (Sublingual Films, Buccal Tablets, and Lozenges, Oral Sprays); By Application (Pain Management, Smoking Cessation, Angina Pectoris, Others); By End-Use (Hospitals, Ambulatory Centers, Others), By Region; Segment Forecast, 2022 - 2030” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Drug distribution technology advancements have various advantages, including ease of use, convenience, and patient compliance. Medication developers are concentrating on appropriate distribution and packaging alternatives to increase treatment efficiency and provide enhanced patient compliance.
Pharmaceutical and biopharmaceutical businesses are investing heavily in research and development to create new compounds for various therapeutic applications and medication distribution systems. The corporations put a lot of money into R&D in order to bring high-quality, innovative items to the industry. Biopharmaceutical businesses' R&D spending has likewise increased over time, driving the industry forward.
With the rising costs and complexities of developing, patenting, and selling new pharmacological entities, pharmaceutical companies are focusing more on developing and modifying buccal release medication distribution systems while also recognizing the therapeutic benefits of controlled medication delivery.
Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/buccal-drug-delivery-system-market/request-for-sample
In 2021, the hospital's segment led the industry with more than XX% market share. This segment's rise is due to an increase in hospital admissions, particularly geriatric patients, an excess of emergency care supplies, and product creation and research by various community hospitals. Various hospitals research adds to the novelty of the formulation and improves its commercialization. On the other hand, ambulatory centers are predicted to develop fastest during the forecast period, followed by clinics, home health, and over-the-counter medications.
Applied Pharma Research, ARx LLC, AstraZeneca, Bayer AG, ARDEA BIOSCIENCES LIMITED, BioDelivery Sciences International, Inc., Catalent, Dr. Reddy's Laboratories Ltd, F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited., Endo Pharmaceuticals plc, Generex Biotechnology, Indivior PLC, Cynapsus Therapeutics Inc., GlaxoSmithKline plc, MedLab, NAPP PHARMACEUTICALS LIMITED, Novartis AG, Pfizer Inc., Sanofi, Novo Nordisk A/S, and Teva Pharmaceutical Industries Ltd are some of the major players in the market.
In November 2021, Pfizer Inc. and the Medicines Patent Pool (MPP) agreed to a voluntary licensing deal for Pfizer's COVID-19 oral antiviral medication product "PF-07321332," is given along with low-dose drug ritonavir.
By providing sub-licenses to eligible generic pharmaceutical manufacturers, MPP will be able to assist additional production and distribution of the experimental antiviral, pending regulatory authorization or approval, allowing for greater access to the worldwide population. In July 2021, Catalent announced the release of its OptiDoseDesign Solution, a design strategy that blends Catalent's substantial development expertise with data-driven scientific tools.
Polaris Market Research has segmented the buccal drug delivery system market report based on type, application,end-use, and region:
Buccal Drug Delivery System, Type Outlook (Revenue - USD Billion, 2018 - 2030)
Buccal Drug Delivery System, Application Outlook (Revenue - USD Billion, 2018 - 2030)
Buccal Drug Delivery System, End-Use Outlook (Revenue - USD Billion, 2018 - 2030)
Buccal Drug Delivery System, Regional Outlook (Revenue - USD Billion, 2018 - 2030)